{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:12:09Z","timestamp":1794575529638,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["NRF-CRP22-2019-0003"],"award-info":[{"award-number":["NRF-CRP22-2019-0003"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Singapore Ministry of Education","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mechanisms for resistance to cytotoxic cancer drugs are dependent on dynamic changes in the biochemistry of cellular pathways, information which is hard to obtain at the systems level. Here we use a deep functional proteomics implementation of the Cellular Thermal Shift Assay to reveal a range of induced biochemical responses to gemcitabine in resistant and sensitive diffuse large B cell lymphoma cell lines. Initial responses in both, gemcitabine resistant and sensitive cells, reflect known targeted effects by gemcitabine on ribonucleotide reductase and DNA damage responses. However, later responses diverge dramatically where sensitive cells show induction of characteristic CETSA signals for early apoptosis, while resistant cells reveal biochemical modulations reflecting transition through a distinct DNA-damage signaling state, including opening of cell cycle checkpoints and induction of translesion DNA synthesis programs, allowing bypass of damaged DNA-adducts. The results also show the induction of a protein ensemble, labeled the Auxiliary DNA Damage Repair, likely supporting DNA replication at damaged sites that can be attenuated in resistant cells by an ATR inhibitor, thus re-establishing gemcitabine sensitivity and demonstrating ATR as a key signaling node of this response.<\/jats:p>","DOI":"10.1038\/s41467-025-59505-8","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:40:55Z","timestamp":1746607255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["MS CETSA deep functional proteomics uncovers DNA repair programs leading to gemcitabine resistance"],"prefix":"10.1038","volume":"16","author":[{"given":"Ying Yu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalidah","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Van","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Min Vivian","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindaugas","family":"Raitelaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Gerault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Jia Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Devaprasath","family":"Jeyasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-5264","authenticated-orcid":false,"given":"Wai Leong","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-702X","authenticated-orcid":false,"given":"P\u00e4r","family":"Nordlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-6552","authenticated-orcid":false,"given":"Nayana","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"59505_CR1","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LAustin Doyle","year":"1998","unstructured":"Doyle, L. A. ustin et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665\u201315670 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59505_CR2","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/sj.leu.2403977","volume":"19","author":"W Bardenheuer","year":"2005","unstructured":"Bardenheuer, W. et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19, 2281\u20132288 (2005).","journal-title":"Leukemia"},{"key":"59505_CR3","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","volume":"23","author":"Y Pommier","year":"2004","unstructured":"Pommier, Y., Sordet, O., Antony, S., Hayward, R. L. & Kohn, K. W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23, 2934\u20132949 (2004).","journal-title":"Oncogene"},{"key":"59505_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR Mutation and Resistance of Non\u2013Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"59505_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007).","journal-title":"Science"},{"key":"59505_CR6","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).","journal-title":"Science"},{"key":"59505_CR7","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1158\/0008-5472.CAN-08-0985","volume":"69","author":"E Peterson-Roth","year":"2009","unstructured":"Peterson-Roth, E., Brdlik, C. M. & Glazer, P. M. Src-induced cisplatin resistance mediated by cell-to-cell communication. Cancer Res. 69, 3619 (2009).","journal-title":"Cancer Res."},{"key":"59505_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1535-6108(03)00058-8","volume":"3","author":"CA Sherman-Baust","year":"2003","unstructured":"Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377\u2013386 (2003).","journal-title":"Cancer Cell"},{"key":"59505_CR9","first-page":"1","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics. Sig. Transduct. Target. Ther. 2023 8:1 8, 1\u20133 (2023).","journal-title":"Sig. Transduct. Target. Ther. 2023 8:1"},{"key":"59505_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nchembio.779","volume":"8","author":"SA Wacker","year":"2012","unstructured":"Wacker, S. A., Houghtaling, B. R., Elemento, O. & Kapoor, T. M. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat. Chem. Biol. 8, 235\u2013237 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"59505_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tig.2015.11.003","volume":"32","author":"X Hu","year":"2016","unstructured":"Hu, X. & Zhang, Z. Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches. Trends Genet. 32, 127\u2013137 (2016).","journal-title":"Trends Genet."},{"key":"59505_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L De Sousa Cavalcante","year":"2014","unstructured":"De Sousa Cavalcante, L. & Monteiro, G. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741, 8\u201316 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"59505_CR13","first-page":"259","volume":"9","author":"RL Soiza","year":"2018","unstructured":"Soiza, R. L., Donaldson, A. I. C. & Myint, P. K. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Therapeutic Adv. Vaccines 9, 259\u2013261 (2018).","journal-title":"Therapeutic Adv. Vaccines"},{"key":"59505_CR14","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800 (2017).","journal-title":"Blood"},{"key":"59505_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/10428194.2016.1193852","volume":"58","author":"AA Moccia","year":"2017","unstructured":"Moccia, A. A. et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed\/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk. Lymphoma 58, 324\u2013332 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"59505_CR16","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NM Cerqueira","year":"2007","unstructured":"Cerqueira, N. M., Fernandes, P. A. & Ramos, M. J. Understanding Ribonucleotide Reductase Inactivation by Gemcitabine. Chem. A Eur. J. 13, 8507\u20138515 (2007).","journal-title":"Chem. A Eur. J."},{"key":"59505_CR17","doi-asserted-by":"publisher","first-page":"815,","DOI":"10.3390\/biom12060815","volume":"12","author":"SE Huff","year":"2022","unstructured":"Huff, S. E., Winter, J. M. & Dealwis, C. G. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules 12, 815, (2022).","journal-title":"Biomolecules"},{"key":"59505_CR18","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1073\/pnas.0600440103","volume":"103","author":"H Xu","year":"2006","unstructured":"Xu, H., Faber, C., Uchiki, T., Racca, J. & Dealwis, C. Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc. Natl Acad. Sci. USA 103, 4028\u20134033 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59505_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"59505_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy, A. et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 171, 481\u2013494.e15 (2017).","journal-title":"Cell"},{"key":"59505_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1146\/annurev-biochem-062917-012837","volume":"88","author":"L Dai","year":"2019","unstructured":"Dai, L., Prabhu, N., Yu, L. Y., Bacanu, S., Ramos, A. D. & Nordlund, P. Horizontal Cell Biology: Monitoring Global Changes of Protein Interaction States with the Proteome-Wide Cellular Thermal Shift Assay (CETSA). Annu. Rev. Biochem. 88, 383\u2013408 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"59505_CR22","doi-asserted-by":"publisher","first-page":"114784","DOI":"10.1016\/j.celrep.2024.114784","volume":"43","author":"AD Ramos","year":"2024","unstructured":"Ramos, A. D. et al. Resource Proteome-wide CETSA reveals diverse apoptosis- inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery ll ll Proteome-wide CETSA reveals diverse apoptosis- inducing mechanisms converging on an initial apopto. Cell Rep. 43, 114784 (2024).","journal-title":"Cell Rep."},{"key":"59505_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cell.2018.03.065","volume":"173","author":"L Dai","year":"2018","unstructured":"Dai, L. et al. Modulation of Protein-Interaction States through the Cell Cycle. Cell 173, 1481\u20131494.e13 (2018).","journal-title":"Cell"},{"key":"59505_CR24","doi-asserted-by":"publisher","first-page":"16874","DOI":"10.1074\/jbc.M109.094391","volume":"285","author":"M Garcia-Diaz","year":"2010","unstructured":"Garcia-Diaz, M., Murray, M. S., Kunkel, T. A. & Chou, K. M. Interaction between DNA Polymerase \u03bb and Anticancer Nucleoside Analogs. J. Biol. Chem. 285, 16874 (2010).","journal-title":"J. Biol. Chem."},{"key":"59505_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/genes15020167","volume":"15","author":"VJ Fousek-Schuller","year":"2024","unstructured":"Fousek-Schuller, V. J. & Borgstahl, G. E. O. The Intriguing Mystery of RPA Phosphorylation in DNA Double-Strand Break Repair. Genes 15, 167 (2024).","journal-title":"Genes"},{"key":"59505_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0410-1","volume":"16","author":"JY Chen","year":"2014","unstructured":"Chen, J. Y., Li, C. F., Kuo, C. C., Tsai, K. K., Hou, M. F. & Hung, W. C. Cancer\/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 16, 410 (2014).","journal-title":"Breast Cancer Res."},{"key":"59505_CR27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.4161\/cbt.200","volume":"2","author":"BBS Zhou","year":"2003","unstructured":"Zhou, B. B. S., Anderson, H. J. & Roberge, M. Targeting DNA Checkpoint Kinases in Cancer Therapy. Cancer Biol. Ther. 2, S16\u20132 (2003).","journal-title":"Cancer Biol. Ther."},{"key":"59505_CR28","doi-asserted-by":"crossref","unstructured":"Liang, Y. et al. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity, Cell Chem. Biol. 29, 572\u2013585.e8 (2021)","DOI":"10.1016\/j.chembiol.2021.06.007"},{"key":"59505_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature10623","volume":"480","author":"DC Goldstone","year":"2011","unstructured":"Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379\u2013382 (2011).","journal-title":"Nature"},{"key":"59505_CR30","doi-asserted-by":"publisher","first-page":"E10022","DOI":"10.1073\/pnas.1805593115","volume":"115","author":"KM Knecht","year":"2018","unstructured":"Knecht, K. M. et al. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc. Natl Acad. Sci. USA 115, E10022\u2013E10031 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59505_CR31","doi-asserted-by":"publisher","first-page":"e10419","DOI":"10.15252\/emmm.201910419","volume":"12","author":"SG Rudd","year":"2020","unstructured":"Rudd, S. G. et al. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. EMBO Mol. Med. 12, e10419 (2020).","journal-title":"EMBO Mol. Med."},{"key":"59505_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvp043","volume":"146","author":"M Suzuki","year":"2009","unstructured":"Suzuki, M. et al. PCNA Mono-ubiquitination and Activation of Translesion DNA Polymerases by DNA Polymerase \u03b1. J. Biochem. 146, 13 (2009).","journal-title":"J. Biochem."},{"key":"59505_CR33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez, Y. et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol. Cancer Therapeutics 17, 1670 (2018).","journal-title":"Mol. Cancer Therapeutics"},{"key":"59505_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.chembiol.2021.06.007","volume":"29","author":"YY Liang","year":"2022","unstructured":"Liang, Y. Y. et al. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chem. Biol. 29, 572\u2013585.e8 (2022).","journal-title":"Cell Chem. Biol."},{"key":"59505_CR35","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1073\/pnas.1324001111","volume":"111","author":"YS Lee","year":"2014","unstructured":"Lee, Y. S., Gregory, M. T. & Yang, W. Human Pol \u03b6 purified with accessory subunits is active in translesion DNA synthesis and complements Pol \u03b7 in cisplatin bypass. Proc. Natl Acad. Sci. USA 111, 2954\u20132959 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59505_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-021-25904-w","volume":"12","author":"PA Konstantinopoulos","year":"2021","unstructured":"Konstantinopoulos, P. A. et al. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat. Commun. 12, 8\u201315 (2021).","journal-title":"Nat. Commun."},{"key":"59505_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 957 (2020).","journal-title":"Lancet Oncol."},{"key":"59505_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/bib\/bbae128","volume":"25","author":"MA Gerault","year":"2024","unstructured":"Gerault, M. A., Granjeaud, S., Camoin, L., Nordlund, P. & Dai, L. IMPRINTS.CETSA and IMPRINTS.CETSA.app: an R package and a Shiny application for the analysis and interpretation of IMPRINTS-CETSA data. Brief. Bioinforma. 25, 128 (2024).","journal-title":"Brief. Bioinforma."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59505-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59505-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59505-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T11:06:48Z","timestamp":1751627208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59505-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59505"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59505-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4820265\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, affiliation 3 was incorrectly listed as one of Wai Leong Tam's affiliations, and has now been corrected to affiliation 2 (Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome 138672, Singapore). Similarly, affiliation 2 was wrongly included in P\u00e4r Nordlund's affiliations, and has now been corrected to affiliation 3 (Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden). These corrections have been made to the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.N. is the inventor of patents related to the CETSA method and is a cofounder and board member of Pelago Biosciences AB. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4234"}}